Anti-topoisomerase I antibodies in silica-associated systemic sclerosis. A model for autoimmunity

N J McHugh, J Whyte, G Harvey, U F Haustein

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To determine the frequency and type of autoantibodies present in patients with systemic sclerosis (SSc) associated with an established environmental toxin.

METHODS: Clinical data and sera were available from 14 men with silica-associated SSc who had developed SSc after at least 2 years of exposure to silica at work. Controls included 27 men with silicosis without SSc. Autoantibodies were measured by immunodiffusion, immunoblotting, and functional inhibition of topoisomerase I (topo I).

RESULTS: Nine of the 14 patients with silica-associated SSc had anti-topo I antibodies. All anti-topo I antibodies in the patients with silica-associated SSc and in 14 anti-topo I-positive patients with idiopathic SSc were directed at an active site of topo I, or at least sterically inhibited its function. One patient with silica-associated SSc had anticentromere antibodies. Unexpectedly, 2 patients with silicosis who had no symptoms of a connective tissue disease had autoantibodies to Ro/SS-A and La/SS-B autoantigens.

CONCLUSION: Anti-topo I antibodies are the predominant autoantibodies present in silica-associated SSc. The generation of anti-topo I antibodies in genetically susceptible individuals may depend partly on the patient's sex and on the site of organ involvement, and may be triggered by silica particles acting as an immune adjuvant.
Original languageEnglish
Pages (from-to)1198-1205
Number of pages8
JournalArthritis & Rheumatism
Volume37
Issue number8
Publication statusPublished - Aug 1994

Fingerprint

Type I DNA Topoisomerase
Systemic Scleroderma
Autoimmunity
Silicon Dioxide
Antibodies
Autoantibodies
Silicosis
Connective Tissue Diseases
Immunodiffusion
Autoantigens
Immunoblotting
Catalytic Domain

Cite this

Anti-topoisomerase I antibodies in silica-associated systemic sclerosis. A model for autoimmunity. / McHugh, N J; Whyte, J; Harvey, G; Haustein, U F.

In: Arthritis & Rheumatism, Vol. 37, No. 8, 08.1994, p. 1198-1205.

Research output: Contribution to journalArticle

McHugh, N J ; Whyte, J ; Harvey, G ; Haustein, U F. / Anti-topoisomerase I antibodies in silica-associated systemic sclerosis. A model for autoimmunity. In: Arthritis & Rheumatism. 1994 ; Vol. 37, No. 8. pp. 1198-1205.
@article{d40a99b7090c4981aadc81675fff9f3c,
title = "Anti-topoisomerase I antibodies in silica-associated systemic sclerosis. A model for autoimmunity",
abstract = "OBJECTIVE: To determine the frequency and type of autoantibodies present in patients with systemic sclerosis (SSc) associated with an established environmental toxin.METHODS: Clinical data and sera were available from 14 men with silica-associated SSc who had developed SSc after at least 2 years of exposure to silica at work. Controls included 27 men with silicosis without SSc. Autoantibodies were measured by immunodiffusion, immunoblotting, and functional inhibition of topoisomerase I (topo I).RESULTS: Nine of the 14 patients with silica-associated SSc had anti-topo I antibodies. All anti-topo I antibodies in the patients with silica-associated SSc and in 14 anti-topo I-positive patients with idiopathic SSc were directed at an active site of topo I, or at least sterically inhibited its function. One patient with silica-associated SSc had anticentromere antibodies. Unexpectedly, 2 patients with silicosis who had no symptoms of a connective tissue disease had autoantibodies to Ro/SS-A and La/SS-B autoantigens.CONCLUSION: Anti-topo I antibodies are the predominant autoantibodies present in silica-associated SSc. The generation of anti-topo I antibodies in genetically susceptible individuals may depend partly on the patient's sex and on the site of organ involvement, and may be triggered by silica particles acting as an immune adjuvant.",
author = "McHugh, {N J} and J Whyte and G Harvey and Haustein, {U F}",
year = "1994",
month = "8",
language = "English",
volume = "37",
pages = "1198--1205",
journal = "Arthritis & Rheumatism",
issn = "0004-3591",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Anti-topoisomerase I antibodies in silica-associated systemic sclerosis. A model for autoimmunity

AU - McHugh, N J

AU - Whyte, J

AU - Harvey, G

AU - Haustein, U F

PY - 1994/8

Y1 - 1994/8

N2 - OBJECTIVE: To determine the frequency and type of autoantibodies present in patients with systemic sclerosis (SSc) associated with an established environmental toxin.METHODS: Clinical data and sera were available from 14 men with silica-associated SSc who had developed SSc after at least 2 years of exposure to silica at work. Controls included 27 men with silicosis without SSc. Autoantibodies were measured by immunodiffusion, immunoblotting, and functional inhibition of topoisomerase I (topo I).RESULTS: Nine of the 14 patients with silica-associated SSc had anti-topo I antibodies. All anti-topo I antibodies in the patients with silica-associated SSc and in 14 anti-topo I-positive patients with idiopathic SSc were directed at an active site of topo I, or at least sterically inhibited its function. One patient with silica-associated SSc had anticentromere antibodies. Unexpectedly, 2 patients with silicosis who had no symptoms of a connective tissue disease had autoantibodies to Ro/SS-A and La/SS-B autoantigens.CONCLUSION: Anti-topo I antibodies are the predominant autoantibodies present in silica-associated SSc. The generation of anti-topo I antibodies in genetically susceptible individuals may depend partly on the patient's sex and on the site of organ involvement, and may be triggered by silica particles acting as an immune adjuvant.

AB - OBJECTIVE: To determine the frequency and type of autoantibodies present in patients with systemic sclerosis (SSc) associated with an established environmental toxin.METHODS: Clinical data and sera were available from 14 men with silica-associated SSc who had developed SSc after at least 2 years of exposure to silica at work. Controls included 27 men with silicosis without SSc. Autoantibodies were measured by immunodiffusion, immunoblotting, and functional inhibition of topoisomerase I (topo I).RESULTS: Nine of the 14 patients with silica-associated SSc had anti-topo I antibodies. All anti-topo I antibodies in the patients with silica-associated SSc and in 14 anti-topo I-positive patients with idiopathic SSc were directed at an active site of topo I, or at least sterically inhibited its function. One patient with silica-associated SSc had anticentromere antibodies. Unexpectedly, 2 patients with silicosis who had no symptoms of a connective tissue disease had autoantibodies to Ro/SS-A and La/SS-B autoantigens.CONCLUSION: Anti-topo I antibodies are the predominant autoantibodies present in silica-associated SSc. The generation of anti-topo I antibodies in genetically susceptible individuals may depend partly on the patient's sex and on the site of organ involvement, and may be triggered by silica particles acting as an immune adjuvant.

M3 - Article

VL - 37

SP - 1198

EP - 1205

JO - Arthritis & Rheumatism

JF - Arthritis & Rheumatism

SN - 0004-3591

IS - 8

ER -